What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

Nov. 8

Weekly Gain

AK Steel (AKS)

$5.38

17%

Geron (GERN -0.56%)

$4.61

17%

Universal Display (OLED 0.09%)

$36.61

16%

3D Systems (DDD -1.15%)

$70.40

12%

Organovo (ONVO -1.19%)

$8.20

10%

Source: Barron's.

Let's start with AK Steel. The producer of flat-rolled carbon, stainless, and electrical steels moved higher after jacking up its prices. AK Steel announced that the current spot market base prices for all of its carbon flat-rolled steel products will increase by $30 per ton. That will improve the company's margins.

Geron moved sharply higher after an abstract posted online showed promising results for its potentially promising myelofibrosis treatment. In a Mayo Clinic study, five of 18 patients in the abstract analysis achieved at least partial remission. The stock had more than doubled at one point, but it gave back most of those gains as the initial euphoric response settled. 

Universal Display lit up the room after posting better-than-expected financial results. It also boosted its outlook. The company has come under fire in the past on concerns that it may lose Samsung as its flagship customer, but the OLED technologist still managed to earn three times as much as Wall Street was forecasting.

3D Systems moved higher as Bloomberg reported on takeover speculation. The company stands out as a leader -- and profitable player -- in 3-D printing. A 3D Systems spokeswoman is quoted in the Bloomberg report, saying that the 3-D printing speedster is "not currently in discussions regarding an acquisition of the company's shares." However, the denial did little to suppress investor demand in the stock.

Finally we have Organovo on the move. This is the third consecutive week that Organovo has cranked out a 10% return. You're not going to see that happen too often. Organovo's goal is ambitious. It wants to give 3-D printing a medical turn, creating a proxy for human tissue that could be used to speed up treatment testing. Organovo's solution may be years away, but it's easy to fathom how popular Organovo will be if it does become the first to market this technology.